Crossing Borders for Duchenne Treatment

Some families with Duchenne muscular dystrophy travel or relocate to another country in search of treatments, clinical trials, or specialized care. The decision is rarely simple. It involves regulatory access, evidence, money, family, and the practicalities of medical care in a new system.

This post sketches the considerations. It is not a recommendation to move.

Why families consider it

In countries where certain DMD therapies are not yet available, are not publicly funded, or are restricted to narrow patient groups, some families look abroad. They may consider relocating to a country with broader access, traveling for a specific clinical trial, or pursuing treatment in a major international neuromuscular center.

The cross-border question is shaped by the same factors that shape DMD care everywhere: regulatory status of a therapy, eligibility criteria, payer coverage, the availability of multidisciplinary follow-up, and the family’s own resources.

What “access” actually means

Access is more than a marketing authorization. It depends on regulatory status, payer coverage, eligibility criteria, prescribing centers, and reimbursement pathways. A drug approved by the FDA or EMA is not automatically funded everywhere, and may be restricted to specific genetic subgroups, age ranges, or mobility statuses.

For example, Elevidys, the first FDA-approved gene therapy for DMD, was initially authorized for boys ages 4 and 5 in June 2023, expanded in June 2024, and later subject to a boxed warning and revised indication after reports of fatal liver injury in non-ambulatory patients. (FDA, expanded approval of Elevidys)

Families considering cross-border care need to understand the current eligibility, not the headline approval.

Clinical trials

Some families travel for clinical trials. Trials have their own eligibility rules, monitoring schedules, and obligations.

Visits may be frequent. The drug is usually free during the trial, but travel, accommodation, and lost work income often are not. Some sponsors and patient organizations provide travel support. ClinicalTrials.gov and patient organizations such as Parent Project Muscular Dystrophy and CureDuchenne maintain listings.

For related reading, see the DMD clinical trial reading guide, DMD treatment access by country, and the reported pieces Children Waiting While Time Runs Out and The Same Disease, Different Countries.

Receiving care in another system

Even if a family secures access to a therapy abroad, ongoing care is rarely simple. DMD requires multidisciplinary follow-up: neuromuscular, cardiac, pulmonary, endocrine, rehabilitation, and psychosocial. A medication is one piece of a much larger plan.

Care that begins abroad sometimes needs to continue locally. That requires a willing local team, transferable medical records, prescription rights, and continuity of follow-up. Without those, the benefit of treatment can be undermined.

The family equation

Relocation is not only a medical decision. It involves work, schooling, siblings, language, extended family, finances, and identity. Many families who consider moving abroad eventually return. Others split, with one parent staying home while another travels.

There is no universally correct answer. The choice is best made with the full picture in front of the family, not under the pressure of a single appointment.

Equity and the global picture

The fact that families cross borders for DMD treatment is itself a sign of unequal access. Countries differ in regulatory frameworks, health technology assessment, drug pricing, and rare disease policy. International comparisons can be informative, but they are also painful. They make explicit what is otherwise abstract: that a child’s outcomes can depend on geography.

For more on this, see DMD treatment access by country.

What is still uncertain

This post does not recommend or discourage cross-border treatment. It describes a real choice that some families face.

The decision is most defensible when it is informed, multidisciplinary, and continuous with the rest of the family’s life.

For background, read DMD treatment cost and the DMD clinical trial reading guide.

Disclaimer: This post is informational and does not constitute medical advice. Decisions about diagnosis or treatment must be made with a qualified care team.